Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Kefkowitz M, Starling R, Teerlink J, McMurray JJV, Solomon SD, for the PARADIGM-HF Investigators. Influenze of sacubitril/valsartan (LCZ696) on 30-day readmission after heart failure hospitalization. J Am Coll Cardiol 2016;68:1-8. [Ref.ID 100489]

Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GYH, van Veldhuisen DJ, Shibata MC, Wedel H, Böhm M, Flather MD, on behalf of the Beta-Blockers in Heart Failure Collaborative Group. Effect of age and sex on efficacy and tolerability of ß blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ 2016;352:i1855. [Ref.ID 100194]

McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin - Neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98476]

Jessup M, Komajda FM, McMurray JJV, Packer M. Perspective roundtable: PARADIGM-HF - The experts' discussion. N Engl J Med 2014;371:e15. [Ref.ID 98475]

McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, for the PARADIGM-HF Investigators and Committees. Angiotensin–neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004. [Ref.ID 98005]

Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber F-X, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M, for the SURVIVE Investigators. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE randomized trial. JAMA 2007;297:1883-91. [Ref.ID 79575]

Krum H, Roecker E B, Mohacsi P, Rouleau J L, Tendera M, Coats AJS, Katus HA, Fowler MB, Packer M, for the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effects of initiating carvedilol in patients with severe chronic heart failure. Results from the COPERNICUS study. JAMA 2003;289:712-8. [Ref.ID 65026]

Packer M, Roecker E B. Effects of beta-blocker therapy in severe chronic heart failure. The authors reply. N Engl J Med 2001;345:998-9. [Ref.ID 58711]

Packer M, Coats AJS, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau J L, Tendera M, Castaigne A, Roecker E B, Schultz MK, DeMets DL, for the Carvedilol Prospective Randomized Cumulative Survival Study Group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001;344:1651-8. [Ref.ID 56682]

Yancy CW, Fowler MB, Colucci WS, Gilbert EM, Bristow M R, Cohn JN, Lukas MA, Young ST, Packer M, for the U.S. Carvedilol Heart Failure Study Group. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med 2001;344:1358-65. [Ref.ID 56295]

Packer M, Poole-Wilson P A, Armstrong PW, et al on behalf of the A T L A S Study Group. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation 2000;100:2312-8. [Ref.ID 52243]

Lechat P, Packer M, Chalon S, Cucherat M, Arab T, Boissel JP. Clinical effects of ß-adrenergic blockade in chronic heart failure. A meta-analysis of double-blind, placebo-controlled, randomized trials. Circulation 1998;98:1184-91. [Ref.ID 41007]

Packer M. Treatment of chronic heart failure. Lancet 1993;1:5-8. [Ref.ID 35254]

Packer M. Pathophysiology of chronic heart failure. Lancet 1993;I:1-5. [Ref.ID 35253]

Gilbert EM, Packer M. The use of placebo controls. N Engl J Med 1995;332:61. [Ref.ID 33794]

Packer M. Digoxin in patients with heart failure. The authors reply. N Engl J Med 1997;337:130. [Ref.ID 33456]

Packer M. End of the oldest controversy in medicine. Are we ready to conclude the debate on digitalis?. N Engl J Med 1997;336:575-6. [Ref.ID 31001]

Packer M, Cohn JN, Colucci WS. Carvedilol in patients with chronic heart failure. N Engl J Med 1996;335:1319-20. [Ref.ID 29522]

Packer M, O'Connor CM, Ghali JK, Pressler M L, Carson PE, Belkin RN, Miller AB, Neuberg G W, Frid D, Wertheimer JH, Cropp AB, DeMets DL. Effect of amlodipine on morbidity and mortality in severe chronic heart failure. N Engl J Med 1996;335:1107-14. [Ref.ID 29275]

Packer M, Bristow M R, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, Shusterman NH, for the U.S. Carvedilol Heart Failure Study Group. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. N Engl J Med 1996;334:1349-55. [Ref.ID 26870]